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Effects of neocarzinostatin-chimeric Fab conjugates on the growth of
human pancreatic carcinoma xenografts
E Otsuji, T Yamaguchi, H Tsuruta, Y Yata, H Nishi, K Okamoto, K Taniguchi, M Kato,
T Kotani, K Kitamura and T Takahashi
First Department ofSurgery, Kyoto Prefectural University ofMedicine, Kamigyo-ku, Kyoto 602, Japan.
Summary Neocarzinostatin (NCS) was bound covalently to human/mouse chimeric Fab fragments of MAb
A7 (chA7Fab) directed against human pancreatic carcinoma. The anti-tumour effect of chA7Fab-NCS was
tested in a nude mouse model on pancreatic carcinoma and compared with A7-NCS or NCS alone. The anti-
tumour effect of chA7Fab-NCS increased in a dose-dependent manner and was significantly greater than
either A7-NCS or NCS. Tumour growth was completely suppressed after the administration of chA7Fab-
NCS. An enzyme-linked immunosorbent assay with rabbit anti-mouse immunoglobulin was performed to
examine the antigenicity of chA7Fab. ChA7Fab had less reactivity with rabbit anti-mouse immunoglobulin
than either whole antibody A7 or murine Fab fragments of A7. Thus, chA7Fab-NCS can inhibit human
pancreatic cancer growth in an animal and may be useful for targeting chemotherapy to pancreatic cancer in
humans.
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Pancreatic cancer is one of the most lethal of all cancers.
While new therapeutic methods including chemotherapy,
radiation and hyperthermia have been developed for treating
patients with advanced pancreatic cancer, in most cases they
do not completely suppress cancer growth. Recently, research
has been directed towards the use of monoclonal antibody
(MAb)-drug conjugates for solid tumours (Deguchi et al.,
1987; Apelgren et al., 1990; Ohyanagi et al., 1988). This has
been made possible by the availability of MAbs that
recognise cell surface antigens of carcinomas.
We previously produced MAb A7 directed against human
colonic carcinomas and covalently conjugated it with the
anti-cancer drug, neocarzinostatin (NCS) (Fukuda, 1985). We
have previously reported a high frequency of reactivity of
MAb A7 with human pancreatic cancers. In addition, we
found that the in vivo anti-tumour activity of an A7-NCS
conjugate on antigen-positive human pancreatic carcinoma
was greater than that of NCS alone. However, pancreatic
cancer was still able to grow in the presence of A7-NCS
even although the conjugate inhibited the overall growth of
pancreatic carcinoma xenografts (Otsuji et al., 1993a). One
reason for this insufficient in vivo anti-tumour activity of
A7-NCS could be rapid inactivation of NCS in the blood
(Fujita et al., 1970). Because Fab fragments of MAbs are
better able to penetrate target tumours, they may be suitable
carriers of anti-cancer agents which are rapidly inactivated.
In our previous study, '25I-labelled chA7Fab (chimeric Fab
fragments of MAb A7)-NCS accumulated in tumours more
rapidly than '25I-labelled A7-NCS, and in significantly larger
amounts, 1 h after injection (Otsuji et al., 1994a).
A7-NCS has been used clinically for the treatment of
advanced colorectal cancers. However, human anti-mouse
antibody (HAMA) was detected in all of the patients who
received A7-NCS (Takahashi et al., 1993). HAMA often
increases the clearance of the MAb, reduces MAb tumour
accumulation and results in lower therapeutic efficacy of the
MAb -drug conjugate. Moreover, HAMA production can
cause anaphylactic reactions. Although one may avoid this
problem by the use ofhuman MAbs, such MAbs have shown
limited tumour localisation (McCabe et al., 1988). Another
approach has been to produce Fab fragments of monoclonal
antibodies. Fab fragments lack the Fc portion, which is the
most immunopotent region of the intact MAb (Spiegelberg
and Weigle, 1965). The latest approach has been the
production of human/mouse chimeric antibodies composed
of the antigen-binding variable region from a murine MAb
and the constant region of a human immunoglobulin
(Morrison et al., 1984; Boulianne et al., 1984). Since the
constant region of the mouse/human chimeric antibody is
human, HAMA production should be decreased. We describe
here the potent anti-tumour effects ofchA7Fab-NCS against
human pancreatic carcinoma in a nude mouse model and
decreased antigenicity of chA7Fab-NCS.
Materials and methods
Cell lines
The human pancreatic carcinoma cell line, HPC-YS (Otsuji et
al., 1992), and the human squamous cell carcinoma, KB-2
(Otsuji et al., 1992), were used in this study. HPC-YS was
established from a ductal cell adenocarcinoma of the human
pancreas and was a kind gift from Dr N Yamaguchi
(Research Institute of Neurology and Geriatrics, Kyoto
Prefectural University of Medicine). KB-2 cells were
purchased from the ATCC. Both cell lines were maintained
in RPMI-1640 medium supplemented with 10% fetal bovine
serum (FBS) (Flow Laboratories, Rockville, MD, USA).
Tumour xenografts
Cultured HPC-YS cells were harvested by brief treatment
with EDTA, washed and resuspended in phosphate-buffered
saline (PBS). Approximately 5 x 106 viable cells were injected
s.c. into the left flank of athymic 8-week-old male nude mice
(BALB/C, nu-nu) (SLC, Shizouka, Japan) weighing approxi-
mately 22.7 g. As controls, KB-2 cells were inoculated into
athymic nude mice by the same method. A tumour mass was
detected in all mice injected with HPC-YS or KB-2 cells.
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MAb and its Fabfragments
MAb A7 is an IgG, and has been reported to react with 77%
of human pancreatic carcinomas tested and with 70% of
human colonic carcinomas (Otsuji et al., 1992). MAb A7
does not recognise normal pancreatic tissues (Otsuji et al.,
1990) and is directed against a 42 kDa glycoprotein on the
surface of human pancreatic carcinoma cells (Otsuji et al.,
1992). MAb A7 has no anti-tumour activity (Otsuji et al.,
1990). To produce Fab fragments of MAb A7, papain was
added to A7 in a ratio of 1:100 (weight/weight) in 0.1 M
phosphate buffer containing 0.01 M 2-mercaptoethanol, pH
7.2, and incubated at 37°C for 7 h. After the reaction was
stopped by the addition of 0.014 M iodoacetamide, the
preparation was dialysed in 5 mM disodium hydrogen
phosphate buffer. Fab fragments were separated immediately
by ion exchange chromatography and gel filtration (Otsuji et
al., 1993b).
Preparation andpurification of chA7Fab
ChA7Fab was prepared as previously described (Yamaguchi
et al., 1993). Briefly, the murine light-chain variable-region
gene was joined to a human K light-chain constant-region
gene. The murine heavy chain variable region gene wasjoined
to a human yv heavy-chain constant-region gene to construct
a human-mouse chimeric heavy-chain gene. These plasmid
DNAs were introduced into AH22 yeast cells as described
previously (Okabayashi et al., 1991). After incubation in
YPD medium for 3 days, cellular debris was removed by
centrifugation and chA7Fab was purified using a CM
Sepharose 4B anti-human IgG column.
NCS conjugation to MAb A7 and chA7Fab
MAb A7 was conjugated to NCS with SPDP as described
previously (Kimura et al., 1980). The conjugation ratio used
was 2 mol of NCS per mol of MAb A7, i.e. 7.5 mg of MAb
A7 was bound to 1 mg of NCS. ChA7Fab was conjugated to
NCS as described previously (Yamaguchi et al., 1993). The
conjugation ratio used was 1 mol of NCS per mol of
chA7Fab, i.e. 4.5 mg of chA7Fab was bound to 1 mg of
NCS.
In vivo effects of A7-NCS on HPC-YS tumours
Anti-tumour effects of chA7Fab-NCS were investigated
using nude mice bearing HPC-YS tumours that are known
to react with chA7Fab. Small tumours were detected in all
mice 14 days after inoculation; they were then divided into
five groups: six mice received chA7Fab-NCS conjugate in
PBS (chA7Fab, 2.25 mg kg-'; NCS, 500 jg kg-'), six
received A7-NCS conjugate (A7, 3.75 mg kg-'; NCS,
500 pg kg-'), six received NCS in PBS (500 pg kg-1), six
received chA7Fab in PBS (2.25 mg kg-'), and six received
PBS as a control. The mean tumour size was similar between
different treatment groups. All treatments were given by
intravenous injection into the tail vein in 100 pl of PBS. The
drug solution was administered daily for 5 days. Tumours
were measured (maximum length and width) twice a week
until day 31. Tumour volume (V) was calculated using the
formula, V=(a2 x b)/2, where a was the maximum width and
b was the maximum length. To standardise any variation in
tumour volume, the relative tumour volume (RV) was
calculated using the formula, RV= V2/VI, where VI was the
initial tumour volume and V2 was the tumour volume at any
given time. The data are presented as the mean+standard
error (s.e.). In other experiments, the anti-tumour effects of
twice the concentration of chA7Fab-NCS, A7-NCS and
NCS were tested. Student's t-test was used to determine
statistically significant differences. A P-value <0.05 was
considered significant.
In vivo effects ofA7-NCS on KB-2 tumours
Anti-tumour effects of chA7Fab-NCS on KB-2 tumours,
which do not react with chA7Fab, were investigated. The
chA7Fab conjugate, free NCS solution and PBS were
administered as above, and the size of the tumours was
measured on the same schedule as above.
Antigenicity of MAb A7 and murine and chimeric Fab
fragments of MAb A7
An enzyme-linked immunosorbent assay (ELISA) was
performed using MAb A7 and murine and chimeric Fab
fragments of MAb A7. Various concentrations of MAb A7
and murine and chimeric Fab fragments of MAb A7 in
carbonate-bicarbonate buffer, pH 8.4, were added to 96-well
microtitre plates (Flow Laboratories, MD, USA) and
incubated at 37°C for 2 h. After five washes with 0.05%
Tween 20 in PBS, the wells were treated with 25% Block Ace
(Dainippon Kagaku, Tokyo, Japan) in PBS. Following
removal of Block Ace, the wells were incubated with 100 pl
of peroxidase-labelled rabbit anti-mouse IgG antibody
(Zymed Laboratories, CA, USA) for 30 min. After five
rinses with 0.05% Tween 20 in PBS, 100 pl of the substrate
solution, consisting of 0.1 M citrate buffer, pH 4.0, containing
azinodiethylbenzolin (ABTS) (0.5 mg ml-') and 0.01%
hydrogen peroxide, was added to each well. The absorbance
was read at 414 nm by an automatic immunoreader (Bio-
Rad, CA, USA).
Results
In vivo anti-tumour effects ofA7-NCS on HPC-YS tumours
Tumour volumes on day 31 were larger than at the beginning
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Figure 1 HPC-YS tumour growth curves in mice receiving
intravenous chA7Fab-NCS conjugate (chA7Fab, 2.25mgkg'I;
NCS, 500jgkg-1), A7-NCS conjugate (A7, 3.75mgkg-1; NCS,
500pgkg-1), free NCS (500 igkg-1), chA7Fab (2.25mgkg-1),
or PBS. A statistically significant difference was observed in the
RV on day 31 between mice administered NCS solution, only
chA7Fab or PBS and those receiving chA7Fab-NCS or A7-
NCS (P<0.01). 0, chA7Fab-NCS; A, A7-NCS; O, free NCS;




IDays after tumour inoculation
Figure 2 HPC-YS tumour growth curves in mice receiving
intravenous chA7Fab-NCS conjugate (chA7Fab, 4.5mg kg-1;
NCS, lOOOpgkg-), A7-NCS conjugate (A7, 7.5mgkg 1; NCS,
1000,ugkg-1), or free NCS (1000jugkg-'). Tumour growth was
completely suppressed only in the chA7Fab-NCS treated group.
A statistically significant difference was observed in the RV on
day 31 between mice administered chA7Fab-NCS and all other
groups (P<0.01). 0, chA7Fab-NCS; A, A7-NCS; FL, free
NCS; X, PBS; points, means; bars, s.e.; *, significant difference
(P<0.01).
(RV) in the control mice administered PBS was 6.92+0.38 on
day 31. The RV in mice administered chA7Fab only was
6.28+0.38 on day 31. By contrast, the RV of mice treated
with the chA7Fab-NCS conjugate was 1.87+0.08 while the
RV was 2.78+0.10 and 4.21+0.12 for mice treated with
A7-NCS and NCS alone, respectively. A statistically
significant difference was observed in the RV on day 31
between mice given NCS solution, chA7Fab alone or PBS
and those receiving chA7Fab-NCS or A7-NCS (P<0.01),
but not between the groups treated with chA7Fab-NCS and
A7-NCS (Figure 1).
Figure 2 shows the results for the mice which received
twice the drug doses (chA7Fab, 4.5 mg kg-'; NCS,
1000 ,ug kg-1), A7-NCS (A7, 7.5 mg kg-1; NCS,
1000 ,ug kg-'), free NCS (1000 ,ig kg-') and PBS. The
day 31 RV in these mice were 0.89+0.29, 2.03+0.30,
3.2+0.19 and 7.1+0.46 for the chA7Fab-NCS, A7-NCS,
free NCS and PBS-treated groups, respectively. Tumour
growth was completely suppressed only in the chA7Fab-
NCS-treated group, and this difference was statistically
significant compared with the A7-NCS, NCS and PBS
groups (P<0.01). Although a statistically significant
difference was not observed between the mice treated
with A7-NCS and NCS, the tumours in the former group
tended to be smaller.
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In vivo anti-tumour effect ofA7-NCS on KB-2 tumours
The effects of chA7Fab-NCS, A7-NCS and free NCS on
KB-2 tumours were nearly identical at both doses tested
(Figures 3 and 4).
Antigenicity ofMAb A7, and murine and chimeric Fab
fragments of MAb A7
The chA7Fab-NCS conjugate reacted the least with rabbit
anti-mouse IgG. In contrast, MAb A7 reacted very strongly
in the ELISA (Figure 5).
Discussion
MAb conjugates with chemotherapeutic drugs may improve
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Days after tumour inoculation
Figure 3 KB-2 tumour growth curves in mice receiving
intravenous chA7Fab-NCS conjugate (chA7Fab, 2.25mgkg ;
NCS, 500jgkg-1), A7-NCS conjugate (A7, 3.75mgkg-1; NCS,
500jugkg-1), free NCS (500 ugkg-1), or PBS. 0, chA7Fab-
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Days after tumour inoculation
Figure 4 KB-2 tumour growth curves in mice receiving
intravenous chA7Fab-NCS conjugate (chA7Fab, 4.5mgkg 1;
NCS, 1000 jigkg- ), A7-NCS conjugate iA7, 7.5 mg kg 1; NCS,
l000pjgkg-'), or free NCS (lOOOpgkg- ). 0, chA7Fab-NCS;
AL, A7-NCS; a, free NCS; points, means; bars, s.e.
Anti-tumour effect of ChA7-NCS
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Figure 5 ELISA for the antigenicity of the chA7Fab, murine
Fab fragment of MAb A7, and whole MAb A7 using rabbit anti-
mouse immunoglobulin. 0, chA7Fab; A, murine Fab fragments
of MAb A7; X, MAb A7; points, means; bars, s.d.
localisation of the drug to the tumour and by minimising
their toxic effects; the latter is a major limitation in
conventional chemotherapy. We have conjugated NCS to
MAb A7, which has been used to treat over 80 patients with
colorectal carcinoma. Some of these patients have had a
substantial regression of their tumour (Takahashi et al.,
1993).
We chose the anti-tumour drug NCS because NCS can be
covalently joined to an antibody without destroying its anti-
tumour activity (Jung et al., 1981). NCS has been reported to
contain a non-protein chromophore that is not covalently
bound to the protein and is the active part ofNCS (Napier et
al., 1989; Ohtsuki and Ishida, 1980). Because MAb A7
reacted with 77% of human pancreatic carcinoma cell lines
(Otsuji, et al., 1993a), we investigated the applicability of
MAb A7 for targeting NCS in pancreatic cancer. In general,
the variable fragment of MAbs has the ability to leave the
vascular space rapidly and to penetrate target tumour tissue
(Sutherland et al., 1987). Thus, the Fab fragment of MAb A7
may be able to carry a large amount of a short-acting anti-
cancer drug like NCS directly into the tumour. In a study
(Otsuji et al., 1994a) using pancreatic cancer xenografts in a
nude mouse model, '251-labelled chA7Fab-NCS accumulated
more rapidly and in significantly larger amounts 1 h after
injection, a time when NCS is still active. Moreover, because
chA7Fab-NCS is catabolised more rapidly than A7-NCS,
thus accelerating the clearance of NCS, chA7Fab-NCS can
be administered more often. In this study, the in vivo anti-
tumour effect of chA7Fab-NCS on HPC-YS tumours was
greater than that of A7-NCS and only chA7Fab-NCS
(chA7Fab, 4.5 mg kg-'; NCS, 1000 jug kg-') completely
suppressed tumour growth.
When mice bearing KB-2 tumours, to which MAb A7
does not bind, were studied, an enhanced cytostatic effect of
chA7Fab-NCS was not observed and there was no
significant difference between the effects of chA7Fab-NCS
and the other NCS groups. These results suggest that the
increased anti-tumour effect of chA7Fab-NCS on HPC-YS
was caused by specific antigen-antibody binding.
Murine MAbs administered to humans induce a HAMA
response (Frodin et al., 1986; Lobugli et al., 1986; Blottiere et
al., 1987) that may reduce tumour localisation. Takahashi et
al. (1993) reported previously that HAMA was produced in
all patients who received A7-NCS. Cyclosporin has been
used to suppress the formation of HAMA as reported by
Weiden et al. (1994). However, adverse effects such as
elevation of bilirubin and creatinine and increases in blood
pressure can occur with administration of cyclosporin.
Although some groups have developed methods to produce
human antibodies and reported some promising data
(Hoogenboom and Winter, 1992), they are not widely used
clinically. To reduce HAMA responses potentially, we
produced chA7Fab by recombinant DNA techniques.
Because of the human origin of the shortened Fc portion
of the chimeric Fab fragment of MAb A7, HAMA
production should be decreased when this conjugate is
administered to humans. We could not evaluate any
differences in the antigenicity of intact MAb A7 and the
chimeric Fab fragment of MAb A7 in humans because we
have not yet performed in vivo human experiments. However,
in an immunological study using rabbit anti-mouse antibody,
the antigenicity of the chA7Fab was lower than the intact
MAb A7 or murine Fab fragments of MAb A7. Although
this experiment was performed using an in vitro model and
this situation was somewhat different from the clinical
setting, these results suggest that chA7Fab may be less
antigenic to humans than the intact MAb or the murine Fab
fragment of MAb A7.
We conclude that chA7Fab-NCS can inhibit human
pancreatic cancer growth in an animal xenograft and that
chA7Fab may be useful for targeting chemotherapy to
pancreatic cancer patients.
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